{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T15:39:12Z","timestamp":1762443552010},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Vascular endothelial growth factor (VEGF) expression correlates with microvessel density, stage, malignant ascites, metastasis, and survival in ovarian cancer. By transducing VEGF165 into a nontumorigenic rat ovarian surface epithelial cell line (ROSE199), we investigated the direct effect of an angiogenic phenotype on tumor development. The neu oncogene, which is overexpressed in &amp;gt;30% of ovarian cancers, was used in comparison. Neu-transfected ROSE199 cells showed phenotypic characteristics of transformation in vitro with an abundance of focus-forming units in monolayer cultures and anchorage-independent growth in soft agar. In contrast, VEGF-secreting ROSE199 cells (VR) retained normal morphology and in vitro growth characteristics (e.g., proliferation rate) compared with parental ROSE199 cells. Interestingly, injection of VR cells into athymic mice formed malignant ascites in 100% of the animals when injected into the peritoneum and developed vascularized tumors in 85% of the mice when injected s.c. Furthermore, blocking VEGF-mediated signaling by the Flk-1\/KDR receptor kinase inhibitor SU5416 significantly inhibited the growth of VR tumors. To validate that the proangiogenic switch is responsible for tumor development, the angiogenic phenotype was balanced by the inducible coexpression of endostatin under the control of Tet-activated promoter. Coexpression of endostatin along with VEGF reversed the tumorigenic phenotype of VR cells. These studies show that alterations in the angiogenic characteristics of ovarian surface epithelium may play an important role in the etiology of ovarian cancer, and that inhibition of angiogenesis can be effective in the treatment of epithelial ovarian cancer. [Cancer Res 2007;67(8):3683\u201390]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-3608","type":"journal-article","created":{"date-parts":[[2007,4,17]],"date-time":"2007-04-17T18:39:26Z","timestamp":1176835166000},"page":"3683-3690","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells"],"prefix":"10.1158","volume":"67","author":[{"given":"Jennifer J.","family":"Schumacher","sequence":"first","affiliation":[{"name":"1Pharmacology, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruud P.M.","family":"Dings","sequence":"additional","affiliation":[{"name":"2Biochemistry, Molecular Biology, and Biophysics, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Cosin","sequence":"additional","affiliation":[{"name":"3Obstetrics and Gynaecology, University of Minnesota, Minneapolis, Minnesota and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indira V.","family":"Subramanian","sequence":"additional","affiliation":[{"name":"3Obstetrics and Gynaecology, University of Minnesota, Minneapolis, Minnesota and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Auersperg","sequence":"additional","affiliation":[{"name":"4Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundaram","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"1Pharmacology, Departments of"},{"name":"3Obstetrics and Gynaecology, University of Minnesota, Minneapolis, Minnesota and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2007,4,17]]},"reference":[{"key":"2022061623200482700_B1","doi-asserted-by":"crossref","unstructured":"Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia? Lancet\u20081971; 2: 163.","DOI":"10.1016\/S0140-6736(71)92335-X"},{"key":"2022061623200482700_B2","unstructured":"Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast RC, Jr., Boyer CM. The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol\u20081990; 75: 255\u201362."},{"key":"2022061623200482700_B3","doi-asserted-by":"crossref","unstructured":"Stadel BV. Letter: the etiology and prevention of ovarian cancer. Am J Obstet Gynecol\u20081975; 123: 772\u20134.","DOI":"10.1016\/0002-9378(75)90509-8"},{"key":"2022061623200482700_B4","doi-asserted-by":"crossref","unstructured":"Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocr Relat Cancer\u20082005; 12: 407\u201321.","DOI":"10.1677\/erc.1.00896"},{"key":"2022061623200482700_B5","doi-asserted-by":"crossref","unstructured":"Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol\u20082001; 172: 213\u201322.","DOI":"10.1016\/S0303-7207(00)00340-3"},{"key":"2022061623200482700_B6","doi-asserted-by":"crossref","unstructured":"Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer\u20082002; 97: 163\u20137.","DOI":"10.1002\/ijc.1593"},{"key":"2022061623200482700_B7","doi-asserted-by":"crossref","unstructured":"Nitta M, Katabuchi H, Ohtake H, Tashiro H, Yamaizumi M, Okamura H. Characterization and tumorigenicity of human ovarian surface epithelial cells immortalized by SV40 large T antigen. Gynecol Oncol\u20082001; 81: 10\u20137.","DOI":"10.1006\/gyno.2000.6084"},{"key":"2022061623200482700_B8","doi-asserted-by":"crossref","unstructured":"Kusakari T, Kariya M, Mandai M, et al. C-erbB-2 or mutant Ha-ras induced malignant transformation of immortalized human ovarian surface epithelial cells in vitro. Br J Cancer\u20082003; 89: 2293\u20138.","DOI":"10.1038\/sj.bjc.6601423"},{"key":"2022061623200482700_B9","unstructured":"Connolly DC, Bao R, Nikitin AY, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res\u20082003; 63: 1389\u201397."},{"key":"2022061623200482700_B10","doi-asserted-by":"crossref","unstructured":"Xing D, Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci U S A\u20082005; 102: 6936\u201341.","DOI":"10.1073\/pnas.0502256102"},{"key":"2022061623200482700_B11","doi-asserted-by":"crossref","unstructured":"Xing D, Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res\u20082006; 66: 8949\u201353.","DOI":"10.1158\/0008-5472.CAN-06-1495"},{"key":"2022061623200482700_B12","doi-asserted-by":"crossref","unstructured":"Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature\u20081989; 339: 58\u201361.","DOI":"10.1038\/339058a0"},{"key":"2022061623200482700_B13","doi-asserted-by":"crossref","unstructured":"Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature\u20081993; 362: 841\u20134.","DOI":"10.1038\/362841a0"},{"key":"2022061623200482700_B14","unstructured":"Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res\u20081976; 36: 2807\u201312."},{"key":"2022061623200482700_B15","doi-asserted-by":"crossref","unstructured":"Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell\u20081989; 56: 345\u201355.","DOI":"10.1016\/0092-8674(89)90238-9"},{"key":"2022061623200482700_B16","doi-asserted-by":"crossref","unstructured":"O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell\u20081994; 79: 315\u201328.","DOI":"10.1016\/0092-8674(94)90200-3"},{"key":"2022061623200482700_B17","unstructured":"Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest\u20081996; 74: 1105\u201315."},{"key":"2022061623200482700_B18","unstructured":"Barton DP, Cai A, Wendt K, Young M, Gamero A, De Cesare S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res\u20081997; 3: 1579\u201386."},{"key":"2022061623200482700_B19","unstructured":"Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res\u20081994; 54: 276\u201380."},{"key":"2022061623200482700_B20","unstructured":"Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res\u20081999; 59: 99\u2013106."},{"key":"2022061623200482700_B21","doi-asserted-by":"crossref","unstructured":"Adams AT, Auersperg N. A cell line, ROSE 199, derived from normal rat ovarian surface epithelium. Exp Cell Biol\u20081985; 53: 181\u20138.","DOI":"10.1159\/000163311"},{"key":"2022061623200482700_B22","unstructured":"Chen CA, Okayama H. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques\u20081988; 6: 632\u20138."},{"key":"2022061623200482700_B23","unstructured":"Bradbury JM, Arno J, Edwards PA. Induction of epithelial abnormalities that resemble human breast lesions by the expression of the neu\/erbB-2 oncogene in reconstituted mouse mammary gland. Oncogene\u20081993; 8: 1551\u20138."},{"key":"2022061623200482700_B24","unstructured":"Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res\u20081987; 47: 936\u201342."},{"key":"2022061623200482700_B25","doi-asserted-by":"crossref","unstructured":"Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res\u20082000; 59: 368\u201376.","DOI":"10.1006\/mvre.1999.2233"},{"key":"2022061623200482700_B26","doi-asserted-by":"crossref","unstructured":"Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer\u20081997; 80: 98\u2013106.","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A"},{"key":"2022061623200482700_B27","doi-asserted-by":"crossref","unstructured":"Paley PJ, Goff BA, Gown AM, Greer BE, Sage EH. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol\u20082000; 78: 336\u201341.","DOI":"10.1006\/gyno.2000.5894"},{"key":"2022061623200482700_B28","doi-asserted-by":"crossref","unstructured":"Matias-Guiu X, Prat J. Molecular pathology of ovarian carcinomas. Virchows Arch\u20081998; 433: 103\u201311.","DOI":"10.1007\/s004280050224"},{"key":"2022061623200482700_B29","doi-asserted-by":"crossref","unstructured":"Ozalp SS, Yalcin OT, Basaran GN, Artan S, Kabukcuoglu S, Minsin TH. Prognostic significance of deletion and over-expression of the p53 gene in epithelial ovarian cancer. Eur J Gynaecol Oncol\u20082000; 21: 282\u20136.","DOI":"10.1016\/S0020-7292(00)00309-X"},{"key":"2022061623200482700_B30","unstructured":"King BL, Carter D, Foellmer HG, Kacinski BM. Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. Am J Pathol\u20081992; 140: 23\u201331."},{"key":"2022061623200482700_B31","doi-asserted-by":"crossref","unstructured":"Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer\u20082002; 2: 331\u201341.","DOI":"10.1038\/nrc795"},{"key":"2022061623200482700_B32","doi-asserted-by":"crossref","unstructured":"Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell\u20082004; 6: 171\u201383.","DOI":"10.1016\/j.ccr.2004.07.009"},{"key":"2022061623200482700_B33","unstructured":"Davies BR, Auersperg N, Worsley SD, Ponder BA. Transfection of rat ovarian surface epithelium with erb-B2\/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo. Am J Pathol\u20081998; 152: 297\u2013306."},{"key":"2022061623200482700_B34","doi-asserted-by":"crossref","unstructured":"Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene\u20082000; 19: 3460\u20139.","DOI":"10.1038\/sj.onc.1203685"},{"key":"2022061623200482700_B35","doi-asserted-by":"crossref","unstructured":"Zhang L, Yang N, Garcia JR, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol\u20082002; 161: 2295\u2013309.","DOI":"10.1016\/S0002-9440(10)64505-1"},{"key":"2022061623200482700_B36","doi-asserted-by":"crossref","unstructured":"Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation\u20082000; 102: 898\u2013901.","DOI":"10.1161\/01.CIR.102.8.898"},{"key":"2022061623200482700_B37","doi-asserted-by":"crossref","unstructured":"Arbiser JL, Larsson H, Claesson-Welsh L, et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am J Pathol\u20082000; 156: 1469\u201376.","DOI":"10.1016\/S0002-9440(10)65015-8"},{"key":"2022061623200482700_B38","doi-asserted-by":"crossref","unstructured":"Watanabe Y, Dvorak HF. Vascular permeability factor\/vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation. Exp Cell Res\u20081997; 233: 340\u20139.","DOI":"10.1006\/excr.1997.3583"},{"key":"2022061623200482700_B39","doi-asserted-by":"crossref","unstructured":"Kruk PA, Auersperg N. A line of rat ovarian surface epithelium provides a continuous source of complex extracellular matrix. In Vitro Cell Dev Biol Anim\u20081994; 30: 217A\u201325.","DOI":"10.1007\/BF02632043"},{"key":"2022061623200482700_B40","doi-asserted-by":"crossref","unstructured":"Auersperg N, Pan J, Grove BD, et al. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci\u20081999; 96: 6249\u201354.","DOI":"10.1073\/pnas.96.11.6249"},{"key":"2022061623200482700_B41","unstructured":"Auersperg N, Kruk PA, MacLaren IA, Watt FM, Mydral SE. Heterogeneous expression of keratin, involucrin, and extracellular matrix among subpopulations of a poorly differentiated human cervical carcinoma: possible relationships to patterns of invasion. Cancer Res\u20081989; 49: 3007\u201314."},{"key":"2022061623200482700_B42","doi-asserted-by":"crossref","unstructured":"Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis\u20082005; 8: 169\u201382.","DOI":"10.1007\/s10456-005-9001-1"},{"key":"2022061623200482700_B43","doi-asserted-by":"crossref","unstructured":"Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst\u20081995; 87: 506\u201316.","DOI":"10.1093\/jnci\/87.7.506"},{"key":"2022061623200482700_B44","doi-asserted-by":"crossref","unstructured":"Friehs I, Barillas R, Vasilyev NV, Roy N, McGowan FX, del Nido PJ. Vascular endothelial growth factor prevents apoptosis and preserves contractile function in hypertrophied infant heart. Circulation\u20082006; 114: I290\u20135.","DOI":"10.1161\/CIRCULATIONAHA.105.001289"},{"key":"2022061623200482700_B45","doi-asserted-by":"crossref","unstructured":"Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med\u20082006; 12: 939\u201344.","DOI":"10.1038\/nm1447"},{"key":"2022061623200482700_B46","unstructured":"Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor\/vascular permeability factor121. Cancer Res\u20081995; 55: 5296\u2013301."},{"key":"2022061623200482700_B47","doi-asserted-by":"crossref","unstructured":"Ke L, Qu H, Nagy JA, et al. Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Eur J Cancer\u20081996; 32A: 2467\u201373.","DOI":"10.1016\/S0959-8049(96)00391-7"},{"key":"2022061623200482700_B48","unstructured":"Lin P, Sankar S, Shan S, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ\u20081998; 9: 49\u201358."},{"key":"2022061623200482700_B49","doi-asserted-by":"crossref","unstructured":"Machida S, Saga Y, Takei Y, et al. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int J Cancer\u20082005; 114: 224\u20139.","DOI":"10.1002\/ijc.20751"},{"key":"2022061623200482700_B50","doi-asserted-by":"crossref","unstructured":"Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost\u20081997; 78: 672\u20137.","DOI":"10.1055\/s-0038-1657610"},{"key":"2022061623200482700_B51","doi-asserted-by":"crossref","unstructured":"Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest\u20081994; 94: 1320\u20137.","DOI":"10.1172\/JCI117451"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/8\/3683\/2582071\/3683.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/8\/3683\/2582071\/3683.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:29:48Z","timestamp":1655432988000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/8\/3683\/534989\/Modulation-of-Angiogenic-Phenotype-Alters"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,15]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2007,4,17]]},"published-print":{"date-parts":[[2007,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-3608","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,15]]}}}